These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31254971)

  • 1. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.
    Thase ME; Stanford AD; Memisoglu A; Martin W; Claxton A; Bodkin JA; Trivedi MH; Fava M; Yu M; Pathak S
    Neuropsychopharmacology; 2019 Dec; 44(13):2268-2276. PubMed ID: 31254971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
    Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
    Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of opioid modulation in major depressive disorder.
    Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
    Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).
    Zajecka JM; Stanford AD; Memisoglu A; Martin WF; Pathak S
    Neuropsychiatr Dis Treat; 2019; 15():795-808. PubMed ID: 31040679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
    Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
    Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?
    Peckham AM; De La Cruz A; Dufresne RL
    Ment Health Clin; 2018 Jul; 8(4):175-183. PubMed ID: 30155392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
    Lepola U; Hefting N; Zhang D; Hobart M
    Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.
    Serafini G; Adavastro G; Canepa G; De Berardis D; Valchera A; Pompili M; Nasrallah H; Amore M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30111745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
    Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
    J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
    Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
    CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.